Cure My Disease

Don't miss your cure!

 Log in / Sign up

New hope for Hard-to-Treat thyroid cancer: drug slows tumor growth in Late-Stage trial

NCT ID NCT03690388

Disease control Sponsor: Exelixis Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether the drug cabozantinib can slow tumor growth in people with advanced thyroid cancer that no longer responds to standard treatments like radioiodine or other targeted therapies. About 187 participants will receive either cabozantinib or a placebo pill. The goal is to see if the drug delays cancer progression and shrinks tumors.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 3

Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.

Participants

187 people

The number who actually took part.

Started

Oct 2018

Expected to finish

Jul 2026

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

16 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Histologically or cytologically confirmed diagnosis of Differentiated Thyroid Cancer (DTC) 2. Measurable disease according to Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 3. Previously treated with or deemed ineligible for treatment with Iodine- 131 for differentiated thyroid cancer (DTC) 4. Previously treated with at least one of the following vascular endothelial growth factor receptor (VEGFR)-targeting tyrosine kinase inhibitor (TKI) agents for DTC: lenvatinib or sorafenib. Note: Up to two prior VEGFR-targeting TKI agents are allowed 5. Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0 or 1 Exclusion Criteria: 1. Prior treatment with any of the following: Cabozantinib; Selective small-molecule v-raf murine sarcoma viral oncogene homolog B1 (BRAF) kinase inhibitor; More than 2 VEGFR-targeting TKI agents; More than 1 immune checkpoint inhibitor therapy; 1 systemic chemotherapy regimen (given as single agent or in combination with another chemotherapy agent) 2. Receipt of any type of small molecule kinase inhibitor (including investigational kinase inhibitor) within 2 weeks or 5 half-lives of the agent, whichever is longer, before randomization 3. Receipt of any type of anticancer antibody (including investigational antibody) or systemic chemotherapy within 4 weeks before randomization 4. Receipt of radiation therapy for bone metastasis within 2 weeks or any other radiation therapy within 4 weeks before randomization. 5. Known brain metastases or cranial epidural disease unless adequately treated

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Differentiated thyroid cancer are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

differentiated thyroid carcinoma thyroid cancer, nonmedullary, 2 Thyroid Cancer, Papillary thyroid gland follicular carcinoma Thyroid Neoplasms

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Differentiated thyroid cancer

Contacts and locations

Locations

  • Exelixis Clinical Site #1

    Philadelphia, Pennsylvania, 19104, United States

  • Exelixis Clinical Site #10

    Stanford, California, 94305, United States

  • Exelixis Clinical Site #100

    Ghent, 9000, Belgium

  • Exelixis Clinical Site #101

    Taipei, 11490, Taiwan

  • Exelixis Clinical Site #102

    Besançon, 25030, France

  • Exelixis Clinical Site #103

    Milan, 20133, Italy

  • Exelixis Clinical Site #104

    Olomouc, 779 00, Czechia

  • Exelixis Clinical Site #105

    Brno, 656 53, Czechia

  • Exelixis Clinical Site #106

    Omsk, 644013, Russia

  • Exelixis Clinical Site #107

    London, Ontario, N6A 5W9, Canada

  • Exelixis Clinical Site #108

    Naples, 80131, Italy

  • Exelixis Clinical Site #109

    Viagrande, Catania, 95029, Italy

  • Exelixis Clinical Site #11

    Omaha, Nebraska, 68114, United States

  • Exelixis Clinical Site #110

    Milan, 20141, Italy

  • Exelixis Clinical Site #111

    Siena, 53100, Italy

  • Exelixis Clinical Site #112

    Tainan, 71004, Taiwan

  • Exelixis Clinical Site #113

    Seattle, Washington, 98109, United States

  • Exelixis Clinical Site #114

    Madrid, 28027, Spain

  • Exelixis Clinical Site #115

    Milan, 20149, Italy

  • Exelixis Clinical Site #116

    Ribeirão Preto, São Paulo, 14051-140, Brazil

  • Exelixis Clinical Site #117

    Leiden, South Holland, 2333 ZA, Netherlands

  • Exelixis Clinical Site #118

    Morristown, New Jersey, 07962, United States

  • Exelixis Clinical Site #119

    Vienna, 1090, Austria

  • Exelixis Clinical Site #12

    Herston, 4029, Australia

  • Exelixis Clinical Site #120

    Torino, TO, 10126, Italy

  • Exelixis Clinical Site #121

    Tübingen, Baden-Wurttemberg, 72076, Germany

  • Exelixis Clinical Site #122

    Pathum Wan, Bangkok, 10330, Thailand

  • Exelixis Clinical Site #123

    Padova, 35128, Italy

  • Exelixis Clinical Site #124

    Magdeburg, Saxony-Anhalt, 39120, Germany

  • Exelixis Clinical Site #125

    Marburg, Hesse, 35043, Germany

  • Exelixis Clinical Site #126

    Bangkok Noi, Bangkok, 10700, Thailand

  • Exelixis Clinical Site #127

    Roma, 00161, Italy

  • Exelixis Clinical Site #128

    Amsterdam, North Holland, 1081 HV, Netherlands

  • Exelixis Clinical Site #129

    Córdoba, X5000AVE, Argentina

  • Exelixis Clinical Site #13

    Madrid, 28034, Spain

  • Exelixis Clinical Site #130

    Hat Yai, Changwat Songkhla, 90110, Thailand

  • Exelixis Clinical Site #131

    Bonn, 53127, Germany

  • Exelixis Clinical Site #132

    Meldola, Forlì - Cesena, 47017, Italy

  • Exelixis Clinical Site #133

    Ciudad de Mèxico, 06100, Mexico

  • Exelixis Clinical Site #134

    Charleston, South Carolina, 29425, United States

  • Exelixis Clinical Site #135

    Catania, CT, 95122, Italy

  • Exelixis Clinical Site #136

    Tainan, 704, Taiwan

  • Exelixis Clinical Site #137

    Zagreb, 10000, Croatia

  • Exelixis Clinical Site #138

    Zagreb, 10000, Croatia

  • Exelixis Clinical Site #139

    München, 81377, Germany

  • Exelixis Clinical Site #14

    Barcelona, 08035, Spain

  • Exelixis Clinical Site #140

    Porto Alegre, Rio Grande do Sul, 90050-170, Brazil

  • Exelixis Clinical Site #141

    Ratchathewi, Bangkok, 10400, Thailand

  • Exelixis Clinical Site #142

    Timișoara, Timiș County, 300166, Romania

  • Exelixis Clinical Site #143

    Rozzano, Milano, 20089, Italy

  • Exelixis Clinical Site #144

    Genova, GE, 16132, Italy

  • Exelixis Clinical Site #145

    Osijek, 31000, Croatia

  • Exelixis Clinical Site #146

    Bucharest, 011863, Romania

  • Exelixis Clinical Site #147

    Mexico City, 03100, Mexico

  • Exelixis Clinical Site #148

    Mexico City, 06700, Mexico

  • Exelixis Clinical Site #149

    Cluj-Napoca, Cluj, 400015, Romania

  • Exelixis Clinical Site #15

    Warsaw, Masovian Voivodeship, 02-781, Poland

  • Exelixis Clinical Site #150

    Craiova, Dolj, 200385, Romania

  • Exelixis Clinical Site #151

    Dresden, Saxony, 01307, Germany

  • Exelixis Clinical Site #152

    Paris, 75013, France

  • Exelixis Clinical Site #153

    Boston, Massachusetts, 02114, United States

  • Exelixis Clinical Site #154

    Essen, 45147, Germany

  • Exelixis Clinical Site #155

    Aachen, 52074, Germany

  • Exelixis Clinical Site #156

    Würzburg, Bavaria, 97080, Germany

  • Exelixis Clinical Site #157

    Tyumen, Tyumen Oblast, 625041, Russia

  • Exelixis Clinical Site #158

    Tuxtla Gutiérrez, Chiapas, 29038, Mexico

  • Exelixis Clinical Site #159

    Hamburg, 20246, Germany

  • Exelixis Clinical Site #16

    Madrid, 28040, Spain

  • Exelixis Clinical Site #160

    Freiburg im Breisgau, 79106, Germany

  • Exelixis Clinical Site #161

    San Luis Potosí City, 78200, Mexico

  • Exelixis Clinical Site #162

    London, England, SW3 6JJ, United Kingdom

  • Exelixis Clinical Site #163

    Hanover, Lower Saxony, 30625, Germany

  • Exelixis Clinical Site #164

    Chicago, Illinois, 60637, United States

  • Exelixis Clinical Site #17

    St Leonards, New South Wales, 2065, Australia

  • Exelixis Clinical Site #18

    Edmonton, Alberta, T6G 1Z2, Canada

  • Exelixis Clinical Site #19

    Durham, North Carolina, 27710, United States

  • Exelixis Clinical Site #2

    Newport Beach, California, 92658, United States

  • Exelixis Clinical Site #20

    Calgary, Alberta, T2N 4N2, Canada

  • Exelixis Clinical Site #21

    New Haven, Connecticut, 06510, United States

  • Exelixis Clinical Site #22

    Detroit, Michigan, 48202, United States

  • Exelixis Clinical Site #23

    Madrid, 28050, Spain

  • Exelixis Clinical Site #24

    Melbourne, Victoria, 3004, Australia

  • Exelixis Clinical Site #25

    Waratah, New South Wales, 2298, Australia

  • Exelixis Clinical Site #26

    Edegem, 2650, Belgium

  • Exelixis Clinical Site #27

    Namur, 5000, Belgium

  • Exelixis Clinical Site #28

    Hong Kong, Hong Kong

  • Exelixis Clinical Site #29

    Pisa, PI, 56124, Italy

  • Exelixis Clinical Site #3

    Torrance, California, 90502, United States

  • Exelixis Clinical Site #30

    Madrid, 28033, Spain

  • Exelixis Clinical Site #31

    Brussels, 1200, Belgium

  • Exelixis Clinical Site #32

    Dijon, Bourgogne-Franche-Comté, 21079, France

  • Exelixis Clinical Site #33

    Madrid, 28041, Spain

  • Exelixis Clinical Site #34

    Seoul, 05505, South Korea

  • Exelixis Clinical Site #35

    Cascavel, Paraná, 85806-300, Brazil

  • Exelixis Clinical Site #36

    Seoul, 03080, South Korea

  • Exelixis Clinical Site #37

    Pécs, 7624, Hungary

  • Exelixis Clinical Site #38

    Porto Alegre, Rio Grande do Sul, 90110-270, Brazil

  • Exelixis Clinical Site #39

    Porto Alegre, Rio Grande do Sul, 90035-903, Brazil

  • Exelixis Clinical Site #4

    Washington D.C., District of Columbia, 20010, United States

  • Exelixis Clinical Site #40

    São José do Rio Preto, São Paulo, 15090-000, Brazil

  • Exelixis Clinical Site #41

    Jerusalem, 9112001, Israel

  • Exelixis Clinical Site #42

    St Louis, Missouri, 63110, United States

  • Exelixis Clinical Site #43

    Haifa, 3109601, Israel

  • Exelixis Clinical Site #44

    Villejuif, Île-de-France Region, 94805, France

  • Exelixis Clinical Site #45

    Angers, Pays de la Loire Region, 4933, France

  • Exelixis Clinical Site #46

    Budapest, 1122, Hungary

  • Exelixis Clinical Site #47

    São Paulo, 01246-000, Brazil

  • Exelixis Clinical Site #48

    Obninsk, Kaluzhiskiy Region, 249036, Russia

  • Exelixis Clinical Site #49

    Moscow, 117036, Russia

  • Exelixis Clinical Site #5

    Bethlehem, Pennsylvania, 18015, United States

  • Exelixis Clinical Site #50

    Glasgow, Scotland, G12 0YN, United Kingdom

  • Exelixis Clinical Site #51

    Oxford, England, OX3 7LE, United Kingdom

  • Exelixis Clinical Site #52

    Samara, 443031, Russia

  • Exelixis Clinical Site #53

    Moscow, 121309, Russia

  • Exelixis Clinical Site #54

    Lexington, Kentucky, 40536, United States

  • Exelixis Clinical Site #55

    Kislino, Kursk Oblast, 305524, Russia

  • Exelixis Clinical Site #56

    Naples, 80131, Italy

  • Exelixis Clinical Site #57

    Sheffield, S10 2SJ, United Kingdom

  • Exelixis Clinical Site #58

    Petah Tikva, 4941492, Israel

  • Exelixis Clinical Site #59

    Poznan, Greater Poland Voivodeship, 60-355, Poland

  • Exelixis Clinical Site #6

    Tampa, Florida, 33612, United States

  • Exelixis Clinical Site #60

    Cardiff, Wales, CF14 2TL, United Kingdom

  • Exelixis Clinical Site #61

    Gliwice, Silesian Voivodeship, 44-101, Poland

  • Exelixis Clinical Site #62

    Salzburg, 5020, Austria

  • Exelixis Clinical Site #63

    Columbia, Missouri, 65212, United States

  • Exelixis Clinical Site #64

    Aberdeen, Scotland, AB25 2ZN, United Kingdom

  • Exelixis Clinical Site #65

    Manchester, M20 4BX, United Kingdom

  • Exelixis Clinical Site #66

    Yaroslavl, 150054, Russia

  • Exelixis Clinical Site #67

    Bordeaux, New Aquitaine, 33075, France

  • Exelixis Clinical Site #68

    Nashville, Tennessee, 37232, United States

  • Exelixis Clinical Site #69

    San Francisco, California, 94115, United States

  • Exelixis Clinical Site #7

    Cincinnati, Ohio, 45219, United States

  • Exelixis Clinical Site #70

    Busan, 49267, South Korea

  • Exelixis Clinical Site #71

    Bristol, England, BS2 8ED, United Kingdom

  • Exelixis Clinical Site #72

    Marseille, Provence-Alpes-Côte d'Azur Region, 13915, France

  • Exelixis Clinical Site #73

    Madrid, 28046, Spain

  • Exelixis Clinical Site #74

    Edegem, 2650, Belgium

  • Exelixis Clinical Site #75

    Pittsburgh, Pennsylvania, 15232, United States

  • Exelixis Clinical Site #76

    Charlotte, North Carolina, 28204, United States

  • Exelixis Clinical Site #77

    Taipei, 10002, Taiwan

  • Exelixis Clinical Site #78

    Detroit, Michigan, 48201, United States

  • Exelixis Clinical Site #79

    Gyeonggi-do, 10408, South Korea

  • Exelixis Clinical Site #8

    Houston, Texas, 77030, United States

  • Exelixis Clinical Site #80

    Ann Arbor, Michigan, 48109, United States

  • Exelixis Clinical Site #81

    Málaga, 29010, Spain

  • Exelixis Clinical Site #82

    Nice, 06189, France

  • Exelixis Clinical Site #83

    Toronto, Ontario, M5G 2M9, Canada

  • Exelixis Clinical Site #84

    Moscow, 125284, Russia

  • Exelixis Clinical Site #85

    Moscow, 155478, Russia

  • Exelixis Clinical Site #86

    Bedford Park, South Australia, 5042, Australia

  • Exelixis Clinical Site #87

    Roma, 00144, Italy

  • Exelixis Clinical Site #88

    Birmingham, England, B15 2TH, United Kingdom

  • Exelixis Clinical Site #89

    Saint Petersburg, 198255, Russia

  • Exelixis Clinical Site #9

    Aurora, Colorado, 80045, United States

  • Exelixis Clinical Site #90

    Anderlecht, 1070, Belgium

  • Exelixis Clinical Site #91

    Lyon, 69373, France

  • Exelixis Clinical Site #92

    Rio de Janeiro, 20231-050, Brazil

  • Exelixis Clinical Site #93

    Orlando, Florida, 32804, United States

  • Exelixis Clinical Site #94

    Miami, Florida, 33136, United States

  • Exelixis Clinical Site #95

    Strasbourg, 67065, France

  • Exelixis Clinical Site #96

    Pergamino, Buenos Aires, B2700CPM, Argentina

  • Exelixis Clinical Site #97

    Caba, C1012AAR, Argentina

  • Exelixis Clinical Site #98

    Sacramento, California, 95817, United States

  • Exelixis Clinical Site #99

    Barcelona, 08036, Spain

More trials for these conditions

Other studies related to the condition(s) this trial covers.